ACRV
Acrivon Therapeutics, Inc. Common Stock
There isn't enough reported data to score ACRV yet.
ACRV Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ACRV's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ACRV PE Valuation
ACRV has no meaningful PE right now: it lost money over the past year.
ACRV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ACRV's losses to shrink, with revenue declining.
ACRV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.88 | +$0.31 |
| Q1 2026 | -$2.00 | +$0.16 |
| Q4 2025 | -$2.02 | +$0.36 |
| Q3 2025 | -$2.07 | +$0.64 |
| Q2 2025 | -$2.19 | +$0.59 |
| Q1 2025 | -$2.16 | +$0.73 |
| Q4 2024 | -$2.38 | +$0.36 |
ACRV is still losing money, but less than at its worst: $1.88 per share over the past year, against $2.89 at its worst in early 2024.
ACRV Quarterly Revenue
ACRV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.9M | +$2.2M |
| Q1 2026 | -$20.6M | -$959K |
| Q4 2025 | -$15.5M | +$2.7M |
| Q3 2025 | -$13.2M | +$5.1M |
| Q2 2025 | -$17.1M | -$3.1M |
| Q1 2025 | -$19.6M | -$1.7M |
| Q4 2024 | -$18.2M | -$4.7M |
| Q3 2024 | -$18.3M | -$8.5M |
ACRV has burned cash in almost every quarter: −$64M over the past year, against −$73M the year before.
ACRV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +3.1M shares |
| 1 year | +8.8% | +3.4M shares |
| 3 years | +90% | +19.9M shares |
ACRV has 42M diluted shares, up 8.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
ACRV Net Leverage
ACRV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ACRV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 14.0 | Oversold |
ACRV's weekly RSI is 41 (neutral) and its Stochastic is 14 (oversold).
ACRV PE vs Healthcare Sector
ACRV has no meaningful PE right now: it lost money over the past year.
ACRV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.76 | 17% below |
| 20 week MA | $1.83 | 20% below |
| 50 week MA | $1.81 | 19% below |
| 100 week MA | $2.28 | 36% below |
| 200 week MA | $5.72 | 74% below |
ACRV is in a downtrend: it's below all five of its weekly moving averages, and 74% below its 200-week average.
ACRV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $15.8 | $11.7 | -26% |
| 2023 | $11.7 | $4.92 | -58% |
| 2024 | $4.92 | $5.92 | +20% |
| 2025 | $5.92 | $2.44 | -59% |
| 2026 YTD | $2.44 | $1.46 | -40% |
ACRV has finished lower in three of the last four years. It's down 40% so far in 2026.